Real-world treatment pattern and outcomes among patients who took tapentadol IR or oxycodone IR

Abstract

Objective:

To evaluate differences in patient characteristics, healthcare resource utilization, and healthcare costs among patients receiving immediate release (IR) formulations of tapentadol (TAP IR) or oxycodone (OXY IR).

Methods:

Patients (≥18 years) who took TAP IR or OXY IR (6/1/2009–7/31/2011) were selected from the OptumInsight Clinformatics Data Mart claims database. Patients were assigned to the TAP IR or OXY IR cohort based on initial drug usage (index event). Continuous health plan coverage 60 days before (baseline period) and after (follow-up period) the index event was required. TAP IR patients were matched to OXY IR patients (1:1) using exact match of key patient characteristics and propensity score matching with patient demographics and clinical characteristics as covariates. T-test and chi-squared test were utilized to evaluate differences in patient characteristics, healthcare utilization and charges among cohorts.

Results:

Patient profiles during the baseline period significantly differed among TAP IR users (n = 17,539) and OXY IR users (n = 85,821) in the overall study population. The matched sample of TAP IR and OXY IR patients (n = 10,185 in both cohorts) had similar patient characteristics. During the 60-day follow-up period, patients who took TAP IR had a shorter mean hospital LOS (0.21 vs 0.35 days, p < 0.0001), a lower mean number of hospitalizations (0.07 vs 0.10, p < 0.0001), and lower mean inpatient ($2900 vs $4382, p < 0.001) and outpatient healthcare charges ($10,550 vs $11,084, p = 0.047). The higher index opioid prescription charge of TAP IR ($190 vs $150, p < 0.0001) was offset by other lower healthcare charges.

Conclusions:

The characteristics of patients who took TAP IR were different from patients who took OXY IR in many respects. In the sub-set of patients matched on demographic and clinical characteristics, those who took TAP IR used healthcare resources to a lesser extent, which was reflected in their lower healthcare charges, relative to OXY IR users.

Keywords::

• Opioid pain medications
• Tapentadol
• Oxycodone
• Healthcare resource utilization
• Healthcare charges

Transparency

Declaration of funding

This research was supported by Janssen Scientific Affairs, LLC.

Declaration of financial/other interests

Jay Lin is an employee of Novosys Health, which has received research funds from Janssen Scientific Affairs, LLC in connection with conducting this study and development of this manuscript. Wing Chow, Myoung Kim, and Marcia Rupnow are employees of Janssen Scientific Affairs, LLC. JME Peer Reviewers on this manuscript have no relevant financial relationships to disclose.

Acknowledgements

The authors acknowledge Melissa Lingohr-Smith from Novosys Health in the editorial support and review of this manuscript.

Previous presentation

A related poster was presented at PAINWeek on September 6, 2012, in Las Vegas, Nevada.